본문 바로가기
KERD
논문KCI 등재

Mechanistic insights into the dual role of CCAR2/DBC1 in cancer

Moon Sue Jin|김정훈|Kim Hwa Jin
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2023.12|Experimental and Molecular Medicine|제55권 |pp. 1691-1701|DOI 10.1038/s12276-023-01058-1

0

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

Cell cycle and apoptosis regulator 2 (CCAR2), also known as deleted in breast cancer 1 (DBC1), has been recently identified as a master regulator of transcriptional processes and plays diverse roles in physiology and pathophysiology, including as a regulator of apoptosis, DNA repair, metabolism, and tumorigenesis. CCAR2 functions as a coregulator of various transcription factors and a critical regulator of numerous epigenetic modifiers. Based on its ability to stimulate apoptosis by activating and stabilizing p53, CCAR2 was initially considered to be a tumor suppressor. However, an increasing number of studies have shown that CCAR2 also functions as a tumor-promoting coregulator by activating oncogenic transcription factors and regulating the enzymatic activity of epigenetic modifiers, indicating that CCAR2 may play a dual role in cancer progression by acting as a tumor suppressor and tumor promoter. Here, we review recent progress in understanding the dual tumor-suppressing and oncogenic roles of CCAR2 in cancer. We discuss CCAR2 domain structures, its interaction partners, and the molecular mechanisms by which it regulates the activities of transcription factors and epigenetic modifiers.

Abstract

Cell cycle and apoptosis regulator 2 (CCAR2), also known as deleted in breast cancer 1 (DBC1), has been recently identified as a master regulator of transcriptional processes and plays diverse roles in physiology and pathophysiology, including as a regulator of apoptosis, DNA repair, metabolism, and tumorigenesis. CCAR2 functions as a coregulator of various transcription factors and a critical regulator of numerous epigenetic modifiers. Based on its ability to stimulate apoptosis by activating and stabilizing p53, CCAR2 was initially considered to be a tumor suppressor. However, an increasing number of studies have shown that CCAR2 also functions as a tumor-promoting coregulator by activating oncogenic transcription factors and regulating the enzymatic activity of epigenetic modifiers, indicating that CCAR2 may play a dual role in cancer progression by acting as a tumor suppressor and tumor promoter. Here, we review recent progress in understanding the dual tumor-suppressing and oncogenic roles of CCAR2 in cancer. We discuss CCAR2 domain structures, its interaction partners, and the molecular mechanisms by which it regulates the activities of transcription factors and epigenetic modifiers.

참고문헌 (123)

  1. Stallcup, M. R., "Gene-specific actions of transcriptional coregulators facilitate physiological plasticity : evidence for a physiological coregulator code", Trends Biochem. Sci, 45, pp.497~510 (2020)
  2. Rosenfeld, M. G., "Sensors and signals : a coactivator", corepressor, Genes Dev, pp.2006, 20[DOI]
  3. Hamaguchi, M., "DBC2, a candidate for a tumor suppressor gene involved in breast cancer", Proc. Natl Acad. Sci. USA, 99, pp.13647~13652 (2002)
  4. Lee, H., "Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma", Hum. Pathol, 42, pp.204~213 (2011)
  5. Kim, H. J., "A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer", Oncogene, 34, pp.4500~4508 (2015)
  6. Johnson, G. S., "CCAR1 and CCAR2 as gene chameleons with antagonistic duality : Preclinical, human translational, and mechanistic basis", Cancer Sci, 111, pp.3416~3425 (2020)
  7. Kim, J. E., "DBC1 is a negative regulator of SIRT1", Nature, 451, pp.583~586 (2008)
  8. Zhao, W., "Negative regulation of the deacetylase SIRT1 by DBC1", Nature, 451, pp.587~590 (2008)
  9. Yu, E. J., "Reciprocal roles of DBC1 and SIRT1 in regulating estrogen receptor alpha activity and co-activator synergy", Nucleic Acids Res, 39, pp.6932~6943 (2011)
  10. Trauernicht, A. M, "Modulation of estrogen receptor alpha protein level and survival function by DBC-1", Mol. Endocrinol, 21, pp.1526~1536 (2007)
  11. Xu, B., "The LIM protein Ajuba recruits DBC1 and CBP", p300 to acetylate ERalpha and enhances ERalpha target gene expression in breast cancer cells, 2019, pp.47, 2322~2335
  12. Fu, J., "Deleted in breast cancer 1, a novel androgen receptor(AR)coactivator that promotes AR DNA-binding activity", J. Biol. Chem, 284, pp.6832~6840 (2009)
  13. Moon, S. J., "DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7", Oncogene, 37, pp.1326~1339 (2018)
  14. Yu, E. J., "Positive regulation of beta-catenin-PROX1 signaling axis by DBC1in colon cancer progression", Oncogene, 35, pp.3410~3418 (2016)
  15. Chini, C. C., "HDAC3 is negatively regulated by the nuclear protein DBC1", J. Biol. Chem, 285, pp.40830~40837 (2010)
  16. Basu, S., "DBC1, p300, HDAC3, and Siah1 coordinately regulate ELL stability and function for expression of its target genes", Proc. Natl Acad. Sci. USA, 117, pp.6509~6520 (2020)
  17. Li, Z., "Inhibition of SUV39H1 methyltransferase activity by DBC1", J. Biol. Chem, 284, pp.10361~10366 (2009)
  18. Nizialek, E. A., "Cancer-predisposition gene KLLN maintains pericentric H3K9 trimethylation protecting genomic stability", Nucleic Acids Res, 44, pp.3586~3594 (2016)
  19. Kim, H. J, "DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300", Nucleic Acids Res, 50, pp.7873~7888 (2022)
  20. Joshi, P., "A functional proteomics perspective of DBC1 as a regulator of transcription", J Proteomics Bioinform, 2, pp.002~ (2013)
  21. Magni, M., "Cell cycle and apoptosis regulator 2 at the interface between DNA damage response and cell physiology", Mutat. Res. Rev. Mutat. Res, 776, pp.1~9 (2018)
  22. Kim, J. E., "p30 DBC is a potential regulator of tumorigenesis", Cell Cycle, 8, pp.2932~2935 (2009)
  23. Chini, E. N., "Deleted in breast cancer-1(DBC-1)in the interface between metabolism, aging and cancer", Biosci. Rep, 33, pp.e00058~ (2013)
  24. Fang, Q., "Advances on the role of the deleted in breast cancer(DBC1)in cancer and autoimmune diseases", J. Leukoc. Biol, 109, pp.449~454 (2021)
  25. Jumper, J., "Highly accurate protein structure prediction with AlphaFold", Nature, 596, pp.583~589 (2021)
  26. Mirdita, M., "ColabFold : making protein folding accessible to all", Nat. Methods, 19, pp.679~682 (2022)
  27. Mannen, T., "Distinct RNA polymerase transcripts direct the assembly of phase-separated DBC1 nuclear bodies in different cell lines", Mol. Biol. Cell, 32, pp.ar33~ (2021)
  28. Mannen, T., "The Sam68 nuclear body is composed of two RNase-sensitive substructures joined by the adaptor HNRNPL", J. Cell Biol, 214, pp.45~59 (2016)
  29. Boija, A., "Transcription factors activate genes through the phase-separation capacity of their activation domains", Cell, 175, pp.1842~1855 (2018)
  30. Sabari, B. R., "Coactivator condensation at super-enhancers links phase separation and gene control", Science, 361, pp.eaar3958~ (2018)
  31. Xue, B., "PONDR-FIT:a meta-predictor of intrinsically disordered amino acids", Biochim. Biophys. Acta, 1804, pp.996~1010 (2010)
  32. Koyama, S., "Repression of estrogen receptor beta function by putative tumor suppressor DBC1", Biochem. Biophys. Res. Commun, 392, pp.357~362 (2010)
  33. Zhang, L. J., "A chicken ovalbumin upstream promoter transcription factor I(COUP-TFI)complex represses expression of the gene encoding tumor necrosis factor alpha-induced protein 8(TNFAIP8)", J. Biol. Chem, 284, pp.6156~6168 (2009)
  34. Sakurabashi, A., "CCAR2 negatively regulates nuclear receptor LXRalpha by competing with SIRT1 deacetylase", J. Steroid Biochem. Mol. Biol, 149, pp.80~88 (2015)
  35. Kong, S., "Deleted in breast cancer 1 suppresses B cell activation through RelB and is regulated by IKKalpha phosphorylation", J. Immunol, 195, pp.3685~3693 (2015)
  36. Hiraike, H., "Identification of DBC1 as a transcriptional repressor for BRCA1", Br. J. Cancer, 102, pp.1061~1067 (2010)
  37. Zheng, H., "hMOF acetylation of DBC1", CCAR2 prevents binding and inhibition of SirT1, 2013, pp.33, 4960~4970
  38. Magni, M., "Chk2 and REGgamma-dependent DBC1 regulation in DNA damage induced apoptosis", Nucleic Acids Res, 42, pp.13150~13160 (2014)
  39. Anantharaman, V., "Analysis of DBC1 and its homologs suggests a potential mechanism for regulation of sirtuin domain deacetylases by NAD metabolites", Cell Cycle, 7, pp.1467~1472 (2008)
  40. Close, P., "DBIRD complex integrates alternative mRNA splicing with RNA polymerase II transcript elongation", Nature, 484, pp.386~389 (2012)
  41. Giguere, S. S., "The proteomic profile of deleted in breast cancer 1(DBC1)interactions points to a multifaceted regulation of gene expression", Mol. Cell. Proteom, 15, pp.791~809 (2016)
  42. Chen, R., "Quantitative proteomics reveals that long non-coding RNA MALAT1 interacts with DBC1 to regulate p53 acetylation", Nucleic Acids Res, 45, pp.9947~9959 (2017)
  43. Santos, L., "A novel form of Deleted in breast cancer 1(DBC1)lacking the N-terminal domain does not bind SIRT1 and is dynamically regulated in vivo", Sci. Rep, 9, pp.14381~ (2019)
  44. McLennan, A. G., "The Nudix hydrolase superfamily", Cell. Mol. Life Sci, 63, pp.123~143 (2006)
  45. Li, J., "A conserved NAD(+)binding pocket that regulates protein-protein interactions during aging", Science, 355, pp.1312~1317 (2017)
  46. Chini, C. C., "DBC1 (Deleted in Breast Cancer 1)modulates the stability and function of the nuclear receptor Rev-erbalpha", Biochem. J, 451, pp.453~461 (2013)
  47. Garcia-Peterson, L. M., "Trending topics of SIRT1 in tumorigenicity", Biochim. Biophys. Acta Gen. Subj, 1865, pp.129952~ (2021)
  48. Kang, H., "Peptide switch is essential for Sirt1 deacetylase activity", Mol. Cell, 44, pp.203~213 (2011)
  49. Nin, V., "Role of deleted in breast cancer 1(DBC1)protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase", J. Biol. Chem, 287, pp.23489~23501 (2012)
  50. Lau, A. W., "SIRT1 phosphorylation by AMP-activated protein kinase regulates p53 acetylation", Am. J. Cancer Res, 4, pp.245~255 (2014)
  51. Yuan, J., "Regulation of SIRT1 activity by genotoxic stress", Genes Dev, 26, pp.791~796 (2012)
  52. Zannini, L., "DBC1 phosphorylation by ATM", ATR inhibits SIRT1 deacetylase in response to DNA damage, 2012, pp.4, 294~303
  53. Park, J. H., "Modification of DBC1 by SUMO2", 3 is crucial for p53-mediated apoptosis in response to DNA damage, 2014, pp.5, 5483~
  54. Liu, X., "Breast cancer metastasis suppressor 1 modulates SIRT1-dependent p53 deacetylation through interacting with DBC1", Am. J. Cancer Res, 6, pp.1441~1449 (2016)
  55. Basu, S., "Negative feedback loop mechanism between EAF1", 2 and DBC1 in regulating ELL stability and functions, 2022, pp.42, e0015122~
  56. Tsai, Y. C., "Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription", Mol. Cell. Proteom, 11, pp.60~76 (2012)
  57. Greco, T. M., "Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation", Mol. Cell. Proteom, 10, pp.M110 004317~ (2011)
  58. 현광범, "Writing, erasing and reading histone lysine methylations", Experimental and Molecular Medicine, 49, pp.1~22 (2017), 생화학분자생물학회
  59. Vaquero, A., "SIRT1 regulates the histone methyl-transferase SUV39H1during heterochromatin formation", Nature, 450, pp.440~444 (2007)
  60. Mulero, M. C., "NF-kappaB, IkappaB, and IKK : integral components of immune system signaling", Adv. Exp. Med. Biol, 1172, pp.207~226 (2019)
  61. Park, S. H., "Regulation of anoikis by deleted in breast cancer-1 (DBC1) through NF-kappaB", Apoptosis, 18, pp.949~962 (2013)
  62. Abuetabh Yasser, "DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities", Experimental and Molecular Medicine, 54, pp.1~12 (2022), 생화학분자생물학회[DOI]
  63. Magni, M., "CCAR2", DBC1 is required for Chk2-dependent KAP1 phosphorylation and repair of DNA damage, 2015, pp.6, 17817~17831
  64. Ryu, J., "CCAR2 controls mitotic progression through spatiotemporal regulation of Aurora B", Cell Death Dis, 13, pp.534~ (2022)
  65. Liu, Y., "p53 modifications : exquisite decorations of the powerful guardian", J. Mol. Cell. Biol, 11, pp.564~577 (2019)
  66. Xia, Z., "Deciphering the acetylation code of p53 in transcription regulation and tumor suppression", Oncogene, 41, pp.3039~3050 (2022)
  67. Qin, B., "DBC1 functions as a tumor suppressor by regulating p53 stability", Cell Rep, 10, pp.1324~1334 (2015)
  68. Wang, F., "Transcriptional", epigenetic regulator CBP, Cell. Mol. Life Sci, pp.2013, 70[DOI]
  69. Shi, D., "CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53", Proc. Natl Acad. Sci. USA, 106, pp.16275~16280 (2009)
  70. Grossman, S. R., "Polyubiquitination of p53 by a ubiquitin ligase activity of p300", Science, 300, pp.342~344 (2003)
  71. Akande, O. E., "DBC1 regulates p53 stability via inhibition of CBP-dependent p53 polyubiquitination", Cell Rep, 26, pp.3323~3335 (2019)
  72. Kumar, S., "Chaperone-assisted E3 ligase CHIP : a double agent in cancer", Genes Dis, 9, pp.1521~1555 (2022)
  73. Sarkar, S., "Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells", Oncogene, 33, pp.26~33 (2014)
  74. Kim Dae-Seok, "Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance", Experimental and Molecular Medicine, 53, pp.1~10 (2021), 생화학분자생물학회[DOI]
  75. Kim Junil, "Gene regulation by histone-modifying enzymes under hypoxic conditions: a focus on histone methylation and acetylation", Experimental and Molecular Medicine, 54, pp.1~12 (2022), 생화학분자생물학회[DOI]
  76. Zhao, S., "The language of chromatin modification in human cancers", Nat. Rev. Cancer, 21, pp.413~430 (2021)
  77. Qunying Jia, "Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms", Experimental and Molecular Medicine, 52, pp.1~11 (2020), 생화학분자생물학회[DOI]
  78. Thompson, P. R., "Regulation of the p300 HAT domain via a novel activation loop", Nat. Struct. Mol. Biol, 11, pp.308~315 (2004)
  79. Froimchuk, E., "Histone H3 lysine 4 methyltransferase KMT2D", Gene, 627, pp.337~342 (2017)
  80. Lee, J. E., "H3K4 mono-and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation", Elife, 2, pp.e01503~ (2013)
  81. Lai, B., "MLL3", MLL4 are required for CBP, Nucleic Acids Res, pp.2017, 45[DOI]
  82. Wang, S. P., "A UTX-MLL4-p300 transcriptional regulatory network coordinately shapes active enhancer landscapes for eliciting transcription", Mol. Cell, 67, pp.308~321 (2017)
  83. Sundararajan, R., "Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling", Oncogene, 24, pp.4908~4920 (2005)
  84. Liu, Q., "Hypoxia-induced proteasomal degradation of DBC1 by SIAH2 in breast cancer progression", Elife, 11, pp.e81247~ (2022)
  85. Menssen, A., "The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop", Proc. Natl Acad. Sci. USA, 109, pp.E187~E196 (2012)
  86. Kandoth, C., "Mutational landscape and significance across 12 major cancer types", Nature, 502, pp.333~339 (2013)
  87. Chen, X., "Mutant p53 in cancer : from molecular mechanism to therapeutic modulation", Cell Death Dis, 13, pp.974~ (2022)
  88. Garapaty, S., "Identification and characterization of a novel nuclear protein complex involved in nuclear hormone receptor-mediated gene regulation", J. Biol. Chem, 284, pp.7542~7552 (2009)
  89. Huan, Y., "DBC1 promotes anoikis resistance of gastric cancer cells by regulating NF-kappaB activity", Oncol. Rep, 34, pp.843~849 (2015)
  90. Frigo, D. E., "Nuclear receptors : from molecular mechanisms to therapeutics", Essays Biochem, 65, pp.847~856 (2021)
  91. Ashton, A. W., "Acetylation of nuclear receptors in health and disease: an update", FEBS J (2022)
  92. Wagle, S., "DBC1", CCAR2 is involved in the stabilization of androgen receptor and the progression of osteosarcoma, 2015, pp.5, 13144~
  93. You, H., "The interaction of canonical Wnt", beta-catenin signaling with protein lysine acetylation, 2022, pp.27, 7~
  94. Levy, L., "Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4interaction", Mol. Cell. Biol, 24, pp.3404~3414 (2004)
  95. Kim, H. J, "DBC1 regulates Wnt", betacatenin-mediated expression of MACC1, a key regulator of cancer progression, in colon cancer, 2018, pp.9, 831~
  96. Zhang, Y., "DBC1 is over-expressed and associated with poor prognosis in colorectal cancer", Int. J. Clin. Oncol, 19, pp.106~112 (2014)
  97. Kim, W., "CCAR2 deficiency augments genotoxic stressinduced apoptosis in the presence of melatonin in non-small cell lung cancer cells", Tumour Biol, 35, pp.10919~10929 (2014)
  98. Kim, W., "Deleted in breast cancer 1(DBC1)deficiency results in apoptosis of breast cancer cells through impaired responses to UV-induced DNA damage", Cancer Lett, 333, pp.180~186 (2013)
  99. Trauernicht, A. M., "DBC-1mediates endocrine resistant breast cancer cell survival", Cell Cycle, 9, pp.1218~1219 (2010)
  100. Kim, W., "CCAR2", DBC1 and Hsp60 positively regulate expression of survivin in neuroblastoma cells, 2019, pp.20, 131~
  101. Kim, W., "Mitochondrial CCAR2", DBC1 is required for cell survival against rotenone-induced mitochondrial stress, 2017, pp.485, 782~789
  102. Hnisz, D., "Super-enhancers in the control of cell identity and disease", Cell, 155, pp.934~947 (2013)
  103. Whyte, W. A., "Master transcription factors and mediator establish superenhancers at key cell identity genes", Cell, 153, pp.307~319 (2013)
  104. Hnisz, D., "Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers", Mol. Cell, 58, pp.362~370 (2015)
  105. Liu, G., "Deleted in breast cancer 1 as a potential prognostic biomarker in human cancers : a pooled analysis of 2, 254patients", Onco Targets Ther, 12, pp.1563~1574 (2019)
  106. Liu, J., "Deleted in breast cancer 1 as a novel prognostic biomarker for digestive system cancers : a meta-analysis", J. Cancer, 10, pp.1633~1641 (2019)
  107. Escande, C., "Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice", J. Clin. Invest, 120, pp.545~558 (2010)
  108. Nin, V., "Deleted in breast cancer 1(DBC1)protein regulates hepatic gluconeogenesis", J. Biol. Chem, 289, pp.5518~5527 (2014)
  109. Escande, C., "Deleted in breast cancer 1 limits adipose tissue fat accumulation and plays a key role in the development of metabolic syndrome phenotype", Diabetes, 64, pp.12~22 (2015)
  110. Ren, J., "DOG 1.0: illustrator of protein domain structures", Cell Res, 19, pp.271~273 (2009)
  111. Kim, S. H., "The overexpression of DBC1in esophageal squamous cell carcinoma correlates with poor prognosis", Histol. Histopathol, 7, pp.49~58 (2012)
  112. Ha, S. Y., "Expression of DBC1 is associated with poor prognosis in hepatitis virus-related hepatocellular carcinoma", Pathol. Res. Pract, 212, pp.616~621 (2016)
  113. Li, C., "Overexpression of DBC1, correlated with poor prognosis, is a potential therapeutic target for hepatocellular carcinoma", Biochem. Biophys. Res. Commun, 494, pp.511~517 (2017)
  114. Cho, D., "The expression of DBC1", CCAR2 is associated with poor prognosis of ovarian carcinoma, 2015, pp.8, 2~
  115. Kim, J. R., "Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas", PLoS ONE, 8, pp.e74738~ (2013)
  116. Noh, S. J., "Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients", Pathology, 45, pp.574~580 (2013)
  117. Park, H. S., "Expression of DBC1 and androgen receptor predict poor prognosis in diffuse large B cell lymphoma", Transl. Oncol, 6, pp.370~381 (2013)
  118. Cha, E. J., "Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma", Clin. Cancer Res, 15, pp.4453~4459 (2009)
  119. 강영란, "Expression of SIRT1 and DBC1 in Gastric Adenocarcinoma", Journal of Pathology and Translational Medicine, 46(6), pp.523~531 (2012), 대한병리학회[DOI]
  120. Pinho, A. V., "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", Oncotarget, 7, pp.74768~74778 (2016)
  121. 심의재, "Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer", Investigative and Clinical Urology, 54(9), pp.631~637 (2013), 대한비뇨의학회
  122. Won, K. Y., "High DBC1(CCAR2)expression in gallbladder carcinoma is associated with favorable clinicopathological factors", Int. J. Clin. Exp. Pathol, 8, pp.11440~11445 (2015)
  123. Yu, X. M., "The expression of SIRT1 and DBC1 in laryngeal and hypopharyngeal carcinomas", PLoS ONE, 8, pp.e66975~ (2013)

관련 논문AI추천

Multifaceted roles of CCAR family proteins in the DNA damage response and cancerBarrett L., Kee Y., Lugano D., Westerheide S. D.생화학분자생물학회 · Experimental and Molecular Medicine2024 · 제56권 DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunitiesAbuetabh Yasser, Al Yousef Habib, Chai Chengsen, Leng Roger, Persad Sujata, Sergi Consolato M., Wu H. Helena생화학분자생물학회 · Experimental and Molecular Medicine2022 · 제54권 Multifaceted roles of CARM1 beyond histone arginine methylationCho Yena, Kim Yong Kee생화학분자생물학회 · Experimental and Molecular Medicine2025 · 제57권 Tumor-suppressive functions of protein lysine methyltransferases조재열, Aziz Nur, Hong Yo Han, Kim Han Gyung, Kim Ji Hye생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권 Functional roles of CTCF in breast cancer오수민, 오채운, 유경현생화학분자생물학회 · BMB Reports2017 · 제50권 제9호The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis김정훈, 김지민, 박철근, 양정욱, 하상윤, 김빛나리대한암학회 · Cancer Research and Treatment2016 · 제48권 제3호

이 간행물의 다른 논문 (225건)

Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics김성영, Han Yeaeunpp. 1-12Grave-to-cradle: human embryonic lineage tracing from the postmortem bodyKu Eu Jeong, Choi Seock Hwan, Choi Yujin Angelina, Oh Ji Wonpp. 13-21Chromatin and noncoding RNA-mediated mechanisms of gastric tumorigenesisKim Tae-Hee, Loe Adrian Kwan Ho, Zhu Lexinpp. 22-31TPX2 prompts mitotic survival via the induction of BCL2L1 through YAP1 protein stabilization in human embryonic stem cellsCha Hyuk-Jin, Kim Yun-Jeong, Go Young-Hyun, 정호창, Kwon Eun-Ji, Kim Seong-Min, Cheong Hyun Sub, Kim Wantae, Shin Hyoung Doo, Lee Haeseungpp. 32-42ZBTB7A suppresses glioblastoma tumorigenesis through the transcriptional repression of EPB41L5Nam Hae Yun, 김성학, 김승후, 최경철, Park Seung-Ho, Song Ji-Hye, Jeong Ji-Hoon, Kim Hyunhee, Jeong Minseok, Kong Min-Jeong, Son Jihyun, Jeong Ji-Eunpp. 43-54
원문 보기